Advances in experimental treatment of β-thalassaemia

Expert Opinion on Investigational Drugs

Volumn 10, Issue 5, 2001, Pages 925-934

  Rodgers, G P ^a   Saunthararajah, Y ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Histone deacetylase inhibitors; Methyl transferase inhibitors; Sickle cell disease; Thalassaemia; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; ARGININE BUTYRATE; AZACITIDINE; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CYCLODEPSIPEPTIDE; CYTARABINE; CYTIDINE DERIVATIVE; CYTOTOXIC AGENT; DEFERIPRONE; DEFEROXAMINE; DNA; ERYTHROPOIETIN; GLOBULIN; HEMOGLOBIN; HEMOGLOBIN F; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYDROXYUREA; IRON CHELATING AGENT; ISOBUTYRAMIDE; METHOTREXATE; METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; PROPIONIC ACID; SODIUM PHENYLBUTYRATE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BETA THALASSEMIA; BLOOD TRANSFUSION; CHROMATIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENT; DNA MODIFICATION; DRUG COST; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PULSE THERAPY; EDEMA; ERYTHROPOIESIS; GENE; GLOBIN SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON CHELATION; NAUSEA; NEUTROPENIA; NONHUMAN; PREVALENCE; REVIEW; SOMNOLENCE; STEM CELL; THALASSEMIA MAJOR;

AZACITIDINE; BETA-THALASSEMIA; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; HISTONE DEACETYLASES; HUMANS; HYDROXYUREA; IRON CHELATING AGENTS;

EID: 0035003466     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.5.925     Document Type: Review

References (54)

1. A series of cases of splenomegaly in children with anemia and peculiar bone changes
2. α-Thalassemia
3. Changing outcome of homozygous alpha-thalassemia: Cautious optimism
4. Generation of a high-titre retroviral vector capable of expressing high levels of the human γ-globin gene
5. Expression of the human γ-globin gene after retroviral transfer to transformed erythroid cells
6. Development of viral vectors for gene therapy of β-chain hemoglobinopathies: Optimization of a γ-globin gene expression cassette
7. The clinical management of thalassemia
8. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major
9. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
10. Marrow transplantation for thalassemia
11. Marrow transplantation in patients with advanced thalassemia
12. Mechanism of HbF stimulation by S-stage compounds: In vitro studies with bone marrow cells exposed to 5-azacytidine, ara-C, or hydroxyurea
13. Interaction of heterocellular hereditary persistence of fetal haemoglobin with β-thalassemia and sickle cell anemia
14. Altering gene expression with 5-azacytidine
15. DNA methylation in the human globin locus in erythroid and nonerythroid tissues
16. 5-Azacytidine stimulates fetal hemoglobin (Hb F) synthesis in anemic baboons
17. Brief report: Treatment with azacytidine of patients with end-stage thalassemia
18. DNA methylation and globin gene expression in patients treated with 5-azacytidine
19. 5-Azacytidine selectively increases gamma globin synthesis in a patient with β+ thalassemia
20. The tumorigenicity of 5-azacytidine in the male Fischer rat
21. Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues
22. 5-Azacytidine potentiates initiation induced by carcinogens in rat liver
23. Effect of 5-azacytidine on the progressive nature of cell transformation
24. Suppression of intestinal neoplasia by DNA hypomethylation
25. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase
26. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia
27. Hydroxyurea induction of hemoglobin F production in sickle cell disease: Relationship between cytotoxicity and F cell production
28. Regression of extramedullary haemopoiesis and augmentation of fetal hemoglobin concentration during hydroxyurea therapy in β-thalassemia
29. Hydroxyurea therapy in β-thalassemia intermedia: Improvement in haematological parameters due to enhanced β-globin synthesis
30. Oral sodium phenylbutyrate therapy in homozygous beta-thalassemia: A clinical trial
31. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders
32. Fetal hemoglobin induction with butyric acid: Efficacy and toxicity
33. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
34. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies
35. Oral isobutyramide reduces transfusion requirements in some patients with homozygous β-thalassemia
36. Treatment of thalassemia major with phenylbutyrate and hydroxyurea
37. Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase
38. The role of recombinant human erythropoietin in the treatment of thalassemia
39. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia
40. Recombinant erythropoietin trial in children with transfusion-dependent homozygous β-thalassemia
41. Administration of high doses of recombinant human erythropoietin to patients with β-thalassemia intermedia: A preliminary trial
42. The therapeutic potential of iron chelators
43. Deferiprone: A review of its clinical potential in iron overload in β-thalassemia and other transfusion-dependent diseases
44. Iron chelation: New therapies
45. A novel oral iron chelator (ICL670A): Update on a Phase I single dose safety study
46. Synergy of demethylation and histone deacytylase inhibition in the reexpression of genes silenced in cancer
47. Butyrate induces selective transcriptional activation of a hypomethylated embryonic globin gene in adult erythroid cells
48. On the induction of fetal hemoglobin by butyrates: In vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-azaC and araC
49. Effects of butyrate and glucocorticoids on γ- to β-globin gene switching in somatic cell hybrids
50. Hemoglobin switching protocols in thalassemia
51. Novel in vitro assay for the detection of pharmacological inducers of fetal hemoglobin
52. Identification of Id2 as a globin regulatory protein by representational difference analysis of K562 cells induced to express γ-globin with a fungal compound
53. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies
54. Understanding fetal globin gene expression: A step towards effective HbF reactivation in haemoglobinopathies